In 2068, Dr. Taisiya Bondarenko, Director of the Svarog Programme at the Gamaleya Research Centre, submitted her seventh-year interim report to the Soviet Ministry of Health and Roscosmos Joint Directorate. The programme had been commissioned in 2061 on a single premise: the Kuzmin Drive’s propulsion capability would be operationally wasted if crew radiation tolerance remained the limiting factor on mission duration.
The Compound
SVR-3 is a radical scavenger and hematopoietic stimulant, administered prophylactically before extravehicular activity and therapeutically following acute exposure events. Development proceeded through standard preclinical stages (2061–2065); crewed trials began aboard Zvezda in 2066 following full toxicology and dosing safety clearance.
Bondarenko selected the programme’s designation — Svarog, after the smith-god of Slavic tradition — deliberately: “We are not attempting to prevent radiation exposure; the engineering solutions developed over the preceding three decades already manage exposure at the structural level. This office’s work begins where that engineering work ends: after exposure has occurred, or is about to. We are not trying to stop the wound. We are trying to make the body its own forge.”
Results
Across two years of crewed trials, SVR-3 produced a 61% reduction in documented acute radiation syndrome incidence among EVA crew relative to unmedicated historical controls. The more operationally significant finding concerned dose-budget rotation length: prior to SVR-3, EVA crew were limited to approximately 90-day rotations before lifetime exposure limits required rotation off active duty. Under SVR-3, the data supported extending average rotation to 140 days — a 56% extension through pharmacological rather than engineering means, with direct relevance to any future mission architecture requiring extended crew presence beyond cislunar space.
Dual-Benefit and Limits
Bondarenko recommended continued funding for a second-generation compound targeting extended-transit dosing, and urged the Ministry to pursue UN co-funding on a dual-benefit basis: the SVR compound class had substantial terrestrial application in oncology radiotherapy support and industrial nuclear-accident response.
Her closing candor is the document’s most quoted passage: “We have not solved radiation. We have bought time against it, in a currency — bone marrow reserve, DNA repair capacity — that is not infinite and does not renew the way a fuel tank does. Any future communication of this programme’s results, to crew, to mission planners, or to the public, should reflect that limit honestly. Anyone who tells a crew otherwise is selling something, and this office does not intend to be the origin of that claim in any form.”